Combining the anti-PD-1 antibody sintilimab with a pemetrexed-platinum chemotherapy regimen improved survival outcomes in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), interim analysis of the phase III ORIENT-11* trial from China showed.
Tobacco smoking exposure appears to result in lower neoadjuvant chemotherapy response rates as well as higher overall and cancer-specific mortality, according to a systematic review and meta-analysis. Smoking status is also associated with bladder cancer recurrence after radical cystectomy.
In individuals undergoing definitive chemoradiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC), the use of NSAIDs was associated with a significantly better overall survival (OS), a study has shown.
A pilot focus group study has identified several themes indicating universal and unique caregiving experiences among Singaporean parents of children with cancer and those reported in western and other Asian cultures.
The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.
In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.
The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.